Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Allison Bigeh"'
Publikováno v:
JACC: Case Reports, Vol 29, Iss 7, Pp 102268- (2024)
Ischemic heart disease is an important cause of heart failure in pregnancy. Involvement of a cardio-obstetrics team is crucial for managing high-risk pregnant patients with cardiovascular disease. We present a case of cardiogenic shock in a pregnant
Externí odkaz:
https://doaj.org/article/5dcb8cae5ea14d82a0b3ca9a4c3f50d7
Publikováno v:
JACC: Case Reports, Vol 2, Iss 1, Pp 112-115 (2020)
Pericardial effusions are common in pregnancy and often remain asymptomatic. We present a case of cardiac tamponade in a young pregnant female unmasking a diagnosis of primary metastatic lung adenocarcinoma. (Level of Difficulty: Intermediate.)
Externí odkaz:
https://doaj.org/article/40d171fd2c80421abe292b4b272167e2
Publikováno v:
Current Cardiology Reports. 24:1041-1048
Cardiovascular disease remains the leading cause of morbidity and mortality in women. Women were historically underrepresented in landmark trials for which cardiovascular guidelines are based on and are prone to gender-specific risk factors that pred
Publikováno v:
Trends in Cardiovascular Medicine. 30:463-469
Inflammation has a strong role in the development of atherosclerotic cardiovascular disease (ASCVD). Several systemic inflammatory conditions have been linked to an increased risk of ASCVD; however, this has not been well established in Inflammatory
Publikováno v:
Current Cardiology Reports. 22
To summarize gender- and sex-specific differences in the presentation, diagnosis, management, and pathophysiology of women presenting with acute coronary syndrome (ACS). Sex differences exist in many aspects of ACS that impact the identification, tre
Publikováno v:
Current cardiology reports. 22(4)
To summarize differences in plaque depositions, coronary artery calcium (CAC) scoring, and the role of CAC in predicting atherosclerotic cardiovascular disease (ASCVD) mortality in men and women. Women have coronary plaque that is more lipid-rich, de
Publikováno v:
European Heart Journal. 40
Background Left ventricular assist devices (LVADs) improve survival in patients with end-stage heart failure. Despite technological advancements, there is still a high risk of bleeding and thromboembolic events. To minimise device clotting, anticoagu
Publikováno v:
Journal of the American College of Cardiology. 75:3311
Publikováno v:
Journal of the American College of Cardiology. 75:756
Current guidelines lack comparative evidence and do not distinguish between anticoagulation agents (such as enoxaparin) in left ventricular assist devices (LVADs). Our study sought to evaluate the safety of bridging anticoagulation in LVAD patients u
Publikováno v:
Journal of the American College of Cardiology. 75:3413